Inside Big Pharma: What 16 Giants Are Betting On Next

The pharmaceutical industry is one of the largest and most financially powerful sectors globally, accounting for over $3 trillion in combined market capitalization and commanding vast reserves of capital. Here, we present our report “Inside Big Pharma: What 16 Giants Are Betting On Next” that analyses the dynamics of 16 select Big Pharma companies and their R&D and M&A pipelines.

DALL-E 3: What Big Pharma Giants Are Betting On Next.

Link to the report: https://docsend.com/view/ehipjmehzzmfmpm8.

Key findings:

• Revenue growth is strong across the sector, and reached $743B in 2024, up 11% from 2023.
• Eli Lilly leads the sector in both market capitalization and revenue growth, fuelled by its emerging obesity/metabolic franchise
• For several big pharma, revenue is extremely concentrated in a few top performing drugs. For example, 69% of Novo Nordisk’s revenue is concentrated in its top 3 drugs, which are all variants of Semaglutide.
• Across R&D pipelines, oncology remains the largest area of focus, accounting for 37% of all declared projects. The second largest is Immunology and Inflammation, with 20%.
• Small molecules (33%) and antibodies (34%) remain the most popular modalities across declared pipeline projects.
• Despite market sentiment, at least 63 cell and gene therapies are in development.
• Advanced therapeutic modalities such as oligonucleotides, cell and gene therapies, and therapeutic peptides now make up at least 18% of Big Pharma pipelines.
• Novartis is a top innovator with respect to the use of advanced modalities, with 11 cell and gene therapies and 7 oligonucleotides in its pipeline